From:

To:

Subject: RE: Fremanezumab COM [SEC=OFFICIAL] Date: Tuesday, 17 September 2019 9:14:35 AM

**Attachments:** image001.png image002.png

image003.png image004.png

DRAFT 5.06 fremanezumab COM \$47F

## Hi **s22**,

Please find attached the fremanezumab commentary with edits.

...e commentary. Please let us know if there's anything further we can do to help finalise the commentary.

s47F

s47F

s47F

s47F

Sent: Monday, 16 September 2019 5:14 PM

s22 s47F

**Subject:** RE: Fremanezumab COM [SEC=OFFICIAL] thanks for letting me know.

From: \$47F

Sent: Monday, 16 September 2019 5:11 PM

To: \$22 s47F

Cc: \$22

**Subject:** RE: Fremanezumab COM [SEC=OFFICIAL]

We are just finalising the fremanezumab edits and were wondering whether it would be okay to send you the document first thing tomorrow morning?


That would enable us to give it another read through to make sure all the changes flow through

to the main body appropriately.

I'm sorry for the delay – and hope it doesn't put you out too much.

Kind regards,

s47F



From: S22

Sent: Thursday, 12 September 2019 4:09 PM

To: \$47F

Cc: \$22

**Subject:** Fremanezumab COM [SEC=OFFICIAL]

His47F

Please find attached our comments on the fremanezumab commentary. Thanks for your work on this. Please flow any changes made to Executive Summary to main body.

The ACM minutes arrived earlier this week – attached.

Happy to discuss anytime if you have questions.

Can we please have a revised version by Monday?

(s47F - s47C

no need to include in Exec Summ for this one

s47C . They are in main body of COM is ESC members interested).

Kind regards,

s22

**PBAC Secretariat** 

Office of Health Technology Assessment | Technology Assessment & Access Division Australian Government Department of Health

## s22

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."